| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C8A |
| Uniprot No | P07357 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 31-584aa |
| 氨基酸序列 | AATPAAVTCQLSNWSEWTDCFPCQDKKYRHRSLLQPNKFGGTICSGDIWDQASCSSSTTCVRQAQCGQDFQCKETGRCLKRHLVCNGDQDCLDGSDEDDCEDVRAIDEDCSQYEPIPGSQKAALGYNILTQEDAQSVYDASYYGGQCETVYNGEWRELRYDSTCERLYYGDDEKYFRKPYNFLKYHFEALADTGISSEFYDNANDLLSKVKKDKSDSFGVTIGIGPAGSPLLVGVGVSHSQDTSFLNELNKYNEKKFIFTRIFTKVQTAHFKMRKDDIMLDEGMLQSLMELPDQYNYGMYAKFINDYGTHYITSGSMGGIYEYILVIDKAKMESLGITSRDITTCFGGSLGIQYEDKINVGGGLSGDHCKKFGGGKTERARKAMAVEDIISRVRGGSSGWSGGLAQNRSTITYRSWGRSLKYNPVVIDFEMQPIHEVLRHTSLGPLEAKRQNLRRALDQYLMEFNACRCGPCFNNGVPILEGTSCRCQCRLGSLGAACEQTQTEGAKADGSWSCWSSWSVCRAGIQERRRECDNPAPQNGGASCPGRKVQTQAC |
| 预测分子量 | 65.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C8A重组蛋白的示例参考文献(注：文献信息为示例性质，建议通过学术数据库查询真实研究)：
---
1. **标题**：*Expression and Functional Characterization of Recombinant Human Complement Component C8A in Escherichia coli*
**作者**：Smith J, et al.
**摘要**：本研究利用大肠杆菌表达系统成功克隆并表达了重组人C8A蛋白，通过亲和层析纯化获得高纯度产物。功能实验表明，重组C8A可与C8B/C8G亚基组装形成膜攻击复合物(MAC)，并在体外模型中诱导细胞溶解。
2. **标题**：*Structural Insights into C8A’s Role in Complement-Mediated Cytolysis via Cryo-EM*
**作者**：Li X, Wang Y.
**摘要**：通过冷冻电镜技术解析了重组C8A蛋白在MAC中的三维结构，揭示了其与C8β链的相互作用界面，为理解补体系统介导的病原体清除机制提供了分子基础。
3. **标题**：*Recombinant C8A Production in Mammalian Cells for Therapeutic Antibody Validation*
**作者**：Garcia R, et al.
**摘要**：采用HEK293细胞表达具有天然糖基化修饰的重组C8A蛋白，用于筛选靶向补体通路的单克隆抗体，为自身免疫性疾病治疗提供工具蛋白。
4. **标题**：*Role of C8A in Hereditary Complement Deficiencies: Insights from Recombinant Protein Assays*
**作者**：Chen L, et al.
**摘要**：通过重组C8A功能恢复实验，证实了特定基因突变导致C8A功能缺陷，阐明了此类突变与复发性感染疾病的关联性。
---
**提示**：实际研究中建议通过PubMed、Web of Science等平台，以关键词“C8A recombinant protein”“complement component 8 alpha”检索最新文献，重点关注其表达技术、结构功能或疾病应用方向。
**Background of C8A Recombinant Protein**
C8A (Complement Component 8 Alpha Chain) is a critical protein in the human complement system, a part of the innate immune response that enhances pathogen clearance, inflammation, and tissue homeostasis. The complement system’s membrane attack complex (MAC), responsible for lysing pathogens, requires C8 as a key component. C8 is a heterotrimer composed of alpha (C8A), beta (C8B), and gamma (C8G) subunits. C8A, encoded by the *C8A* gene, plays a structural and functional role in MAC assembly. During MAC formation, C8 binds to the C5b-7 complex, facilitating the insertion of C9 polymers into target cell membranes, ultimately forming pores that disrupt membrane integrity.
Recombinant C8A protein is produced using genetic engineering techniques, often expressed in mammalian, bacterial, or insect cell systems to ensure proper folding and post-translational modifications. Its production enables detailed studies of MAC-mediated immune mechanisms, including pathogen neutralization, inflammatory signaling, and unintended host cell damage. Dysregulation of the complement system, including C8A defects, is linked to diseases such as autoimmune disorders, atypical hemolytic uremic syndrome, and susceptibility to bacterial infections.
Research on recombinant C8A has therapeutic implications, aiding in the development of complement-targeted drugs. Inhibitors of MAC components, including C8A, are being explored to mitigate complement-mediated tissue injury in conditions like age-related macular degeneration or ischemia-reperfusion injury. Conversely, recombinant C8A could potentially enhance MAC activity in immunodeficiencies. Its study also contributes to understanding bacterial immune evasion strategies, as pathogens often produce proteins that block MAC formation by interacting with C8. Overall, C8A recombinant protein serves as a vital tool for dissecting complement biology and advancing immunotherapeutic strategies.
×
